[AB1013] SYSTEMIC SCLEROSIS AND MYOSITIS EXTRACTABLE NUCLEAR ANTIGEN (ENA) ANALYSIS: PROFILE OF A COHORT OF SUBJECTS WITH ISOLATED RAYNAUD'S PHENOMENON

R. Gualtierotti[1,2], F. Ingegnoli[1,2], T. Schioppo[1], C. Lubatti[1], S. Zeni[1], C. Mastaglio[3], V. Galbiati[3], C. Grossi[4], M. O. Borghi[4], L. Castelnovo[5], P. L. Meroni[1,2]. [1]Division of Rheumatology, Ist. Ortopedico G. Pini; [2]Dept. of Clinical Sciences and Community Health, University of Milan, Milan; [3]Department of Rheumatology, Ospedale Moriggia-Pelascini, Gravedona; [4]Experimental Laboratory of Immunological and Rheumatologic Researches, Istituto Auxologico Italiano, Milan; [5]UOC Medicina Interna, Presidio Ospedaliero di Saronno, AO di Busto Arsizio, Busto Arsizio, Italy

Background: Raynaud's phenomenon (RP) may predate an overt Connective Tissue Disease (CTD) of the "Scleroderma spectrum" such as Systemic sclerosis (SSc). The predictive role of auto-antibodies (auto-Abs) such as ANA for the development of a CTD in patients with isolated RP (i.e. with no other signs or symptoms of CTD) is well known, whereas data regarding the prevalence of anti-ENA in such patients are lacking.

Objectives: Our aim was to evaluate the profile of anti-ENA in patients with isolated RP.

Methods: Sera were analyzed for anti-ENA by EUROLINE "Scleroderma profile" (antigens: Scl70, CENP A, CENP B, RP11, RP155, fibrillarin (Fib), NOR90, Th/To, PM-Scl100, PM-Scl75, Ku, PDGFR, Ro-52) and "Myosites profile" (antigens: Mi-2, Ku, PM-Scl100, PM-Scl75, Jo-1, SRP, PL-7, PL-12, EJ, OJ, Ro-52) [EUROIMMUN AG Leuback, Germany].

Results: A total of 115 adults (105 females and 10 males) with isolated RP were enrolled in two Italian Rheumatology Centers (G. Pini Institute, Milan and Moriggia-Pelascini Hospital, Gravedona) from March 2011 to September 2013. Forty-four of 115 (38.0%) subjects were positive for at least one anti-ENA; 71 out of 110 (61.7%) were negative both for Scleroderma and Myosites profiles (see table 1 and 2).

Table 1. Scleroderma profile results.

	Scl70	CENP A	CENP B	RP11	RP155	Fib	NOR90	Th
Borderline	3	-	-	1	1	2	1	
Mild positive	1	1	1	-	2	1	1	
Positive	-	1	-	-	-	-	1	
Intensive positive	2	12	12	-	-	-	-	

Table 2. Myosites profile results.

	Mi-2	Ku	PM-Scl100	PM-Scl75	Jo-1	SRP	Pl
Borderline	-	1	2	4	-	2	
Mild positive	1	1	1	1	-	-	
Positive	-	-	2	1	-	-	
Intensive positive	-	1	-	-	-	-	

Conclusions: Up to 38% of RP subjects were positive for at least one anti-ENA. The detection of anti-ENA since the first Rheumatologic evaluation may aid the specialist in achieving an earlier diagnosis.